Skip to main content

Table 1 Clinical and biochemical parameters for participants, according to quartile of ANGPTL8 levels

From: Circulating ANGPTL8 levels and risk of kidney function decline: Results from the 4C Study

Characteristics Q1 (187.78–287.78) Q2 (359.06–436.95) Q3 (517.94–605.04) Q4 (751.47–1057.66) All P value
N 577 579 578 577 2311  
Age (years) 58 (52–64) 60 (53–67) 63 (56–69) 64 (58–71) 62 (55–68)  < 0.001
Male (%) 135 (23.4) 194 (33.5) 240 (41.5) 261 (45.2) 830 (35.9)  < 0.001
BMI (kg/m2) 23.77 (21.67–25.94) 23.34 (21.47–26.14) 23.23 (21.30–25.68) 23.24 (21.17–25.64) 23.43 (21.41–25.81) 0.09
WHR 0.87 (0.83–0.90) 0.87 (0.83–0.90) 0.87 (0.83–0.90) 0.88 (0.83–0.91) 0.87 (0.83–0.90) 0.33
HbA1c (%) 5.70 (5.40–6.00) 5.70 (5.40–6.00) 5.70 (5.50–6.10) 5.70 (5.40–6.20) 5.70 (5.40–6.00) 0.07
FPG (mmol/L) 5.27 (4.92–5.74) 5.22 (4.88–5.71) 5.34 (4.93–6.02) 5.38 (4.94–6.15) 5.28 (4.92–5.91)  < 0.001
2 h PG (mmol/L) 6.18 (5.19 -7.65) 6.32 (5.23–7.68) 6.50 (5.44–8.44) 6.70 (5.55–9.12) 6.43 (5.30–8.16)  < 0.001
HDL (mmol/L) 1.48 (1.26–1.74) 1.44 (1.25–1.70) 1.47 (1.24–1.73) 1.40 (1.17–1.69) 1.45 (1.23–1.71) 0.006
LDL (mmol/L) 2.82 (2.30–3.37) 2.77 (2.27–3.32) 2.80 (2.26–3.33) 2.79 (2.29–3.35) 2.79 (2.28–3.34) 0.88
TG (mmol/L) 1.22 (0.87–1.66) 1.14 (0.81–1.65) 1.08 (0.84–1.63) 1.31 (0.88–1.92) 1.19 (0.85–1.73)  < 0.001
TC (mmol/L) 5.02 (4.35–5.59) 4.94 (4.34–5.58) 4.96 (4.38–5.64) 5.04 (4.32–5.66) 4.99 (4.35–5.62) 0.64
ALT (U/L) 12 (9–17) 12 (9–16) 12 (10–17) 14 (10–19) 13 (10–17)  < 0.001
AST (U/L) 20 (17–24) 21 (18–25) 21 (18–26) 23 (19–28) 21 (18–26)  < 0.001
Creatinine at baseline (μmol/L) 58.50 (54.70–63.45) 59.40 (55.00–64.60) 60.60 (56.10–65.80) 62.30 (56.85–68.30) 60.30 (55.50–65.50)  < 0.001
eGFR at baseline (mL/min/1.73 m2) 99.77 (94.23–105.04) 98.52 (93.35–104.31) 96.72 (91.72–102.07) 94.95 (89.45–100.35) 97.36 (92.19–103.05)  < 0.001
Hypertension (%) 300 (52.0) 301 (52.0) 330 (57.1) 341 (59.1) 1272 (55.0) 0.03
Hyperlipidaemia (%) 213 (36.9) 213 (36.8) 211 (36.5) 260 (45.1) 897 (38.8) 0.005
DM (%) 114 (19.8) 102 (17.6) 153 (26.5) 172 (29.8) 541 (23.4)  < 0.001
CVD (%) 27 (4.7) 30 (5.2) 19 (3.3) 33 (5.7) 109 (4.7) 0.24
Kidney function decline (%) 16 (2.8) 29 (5.0) 25 (4.3) 66 (11.4) 136 (5.9)  < 0.001
CKD stage
 G1 (%) (eGFR≥ 90) 382 (66.2) 355 (61.3) 332 (57.4) 253 (43.8) 1322 (57.2)  < 0.001
 G2 (%) (60 ≤ eGFR < 90) 183 (31.7) 201 (34.7) 229 (39.6) 274 (47.5) 887 (38.4)
 G3 (%) (30 ≤ eGFR < 60) 11 (1.9) 22 ( 3.8) 16 ( 2.8) 47 ( 8.1) 96 (4.2)
 G4 (%) (15 ≤ eGFR < 30) 1 (0.2) 1 ( 0.2) 1 ( 0.2) 2 (0.3) 5 ( 0.2)
 G5 (%)(eGFR < 15) 0 (0) 0 ( 0) 0 ( 0) 1 ( 0.2) 1 ( 0.04)
  1. BMI body-mass index, WHR waist hip rate, HbA1c glycated haemoglobin A1c, FPG fasting plasma glucose, 2 h PG 2 h plasma glucose concentration, HDL high density lipoprotein, LDL low density lipoprotein, TG triglycerides, TC total cholesterol, ALT alanine transaminase, AST aspartate aminotransferase, eGFR glomerular filtration rate, DM diabetes mellitus, CVD cardiovascular diseases, CKD chronic kidney disease